MedPath

SANOFI PASTEUR

SANOFI PASTEUR logo
🇫🇷France
Ownership
Subsidiary
Established
1990-01-01
Employees
10K
Market Cap
-
Website
http://www.sanofipasteur.com
Clinical Trials
Related News

Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India

Phase 3
Completed
Conditions
Influenza
Pandemic Influenza
Influenza A Virus, H1N1 Subtype
Interventions
Biological: A/H1N1 pandemic influenza vaccine (non- adjuvanted)
First Posted Date
2010-01-21
Last Posted Date
2014-01-14
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
100
Registration Number
NCT01053143

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Phase 2
Completed
Conditions
Meningococcal Infection
Meningitis
Interventions
Biological: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)
Biological: M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live
Biological: Varicella Virus Vaccine Live
Biological: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Biological: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Biological: Rotavirus Vaccine
Biological: Hepatitis B Vaccine
First Posted Date
2010-01-14
Last Posted Date
2022-03-28
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
580
Registration Number
NCT01049035

A Study to Assess the Safety of Adacel® Vaccine

Phase 3
Completed
Conditions
Tetanus
Diphtheria
Pertussis
Interventions
Biological: Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)
First Posted Date
2009-12-25
Last Posted Date
2016-05-16
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
30
Registration Number
NCT01040052

Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults

Completed
Conditions
Influenza
Swine-Origin A/H1N1 Influenza Virus
First Posted Date
2009-12-16
Last Posted Date
2015-09-28
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
3934
Registration Number
NCT01032980

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: Influenza Virus Vaccine USP Trivalent Types A and B
First Posted Date
2009-11-11
Last Posted Date
2016-04-14
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
1250
Registration Number
NCT01011049

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

Phase 3
Completed
Conditions
Japanese Encephalitis
Encephalitis
Interventions
Other: Blood sample
Biological: JE-CV administered in Study JEC02
First Posted Date
2009-10-27
Last Posted Date
2017-11-29
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
596
Registration Number
NCT01001988

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Phase 2
Completed
Conditions
Dengue Virus
Dengue
Dengue Hemorrhagic Fever
Dengue Fever
Interventions
Biological: Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
Biological: CYD Dengue Vaccine
First Posted Date
2009-10-12
Last Posted Date
2022-03-24
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
600
Registration Number
NCT00993447

A Study of Influenza Virus Vaccines in Children and Adults

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: 2008-2009 Trivalent Influenza Virus Vaccine
Biological: Quadrivalent Influenza Virus Vaccine
Biological: 2009-2010 Trivalent Influenza Virus Vaccine
First Posted Date
2009-10-02
Last Posted Date
2013-12-12
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
600
Registration Number
NCT00988143

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Phase 2
Completed
Conditions
Influenza
Swine-origin A/H1N1 Influenza
Interventions
Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)
First Posted Date
2009-08-11
Last Posted Date
2014-01-14
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
401
Registration Number
NCT00956046

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Phase 2
Completed
Conditions
Influenza
Swine-origin A/H1N1 Influenza
Interventions
Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Biological: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
First Posted Date
2009-08-11
Last Posted Date
2014-01-14
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Target Recruit Count
303
Registration Number
NCT00956202
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy